Paper Details

  1. Home
  2. Paper Details

A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.

Author: BanksAmy L, BensonDon M, ByrdJohn C, CaligiuriMichael A, ChenLei, EisenbeisCharles F, EmmanouilidesChristos, FerketichAmy K, GarciaPablo, HurstDeborah, KhanKhuda D, LeonardJohn P, MichelsonGlenn, MilanSandra, PiroLawrence, PorcuPierluigi

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the efficacy of combining rituximab with human recombinant interleukin-2 (rIL-2) for the treatment of rituximab-refractory low-grade non-Hodgkin's lymphoma (NHL).
Paper Details　
Original Abstract of the Article :
The incidence of non-Hodgkin's lymphoma (NHL), the fifth most common malignancy in the United States, has increased over 70% in the last 30 years. Fifty percent to 75% of patients with low-grade or follicular NHL respond to rituximab therapy. However, responses are generally of limited duration, and...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1158/1078-0432.CCR-06-1571

データ提供：米国国立医学図書館（NLM）

Exploring New Horizons in Non-Hodgkin's Lymphoma Treatment

Non-Hodgkin's lymphoma (NHL) is a challenging disease, akin to a vast and unforgiving desert. This study investigates the potential of combining rituximab with recombinant interleukin-2 (rIL-2) as a novel treatment strategy for rituximab-refractory indolent NHL. The researchers meticulously designed a large, multicenter phase 2 trial, evaluating the impact of this combination therapy on patient outcomes. Their findings suggest that this combination therapy could offer a promising new avenue for treating rituximab-resistant indolent NHL, potentially improving patient responses and extending survival.

A New Oasis in the Desert of Lymphoma Treatment: The Potential of Rituximab and rIL-2

The study's findings provide a glimmer of hope for patients with rituximab-refractory indolent NHL. The researchers observed an enhancement in rituximab's efficacy when combined with rIL-2, suggesting that this combination could potentially improve patient responses and extend survival. While further research is needed to confirm these findings and optimize the use of this combination therapy, the initial results are promising.

Navigating the Complexities of Lymphoma Treatment

This research highlights the importance of exploring new therapeutic strategies for NHL. The authors' meticulous approach to designing and conducting a large, multicenter phase 2 trial demonstrates their commitment to improving patient outcomes in this challenging area of medicine. The potential benefits of combining rituximab with rIL-2 warrant further investigation and could lead to significant advancements in NHL treatment.

Dr. Camel's Conclusion

The landscape of NHL treatment is ever-changing, like the shifting sands of a desert. This study offers a beacon of hope, suggesting that combining rituximab with rIL-2 could provide a new oasis for patients seeking effective treatment options. Further research is crucial to fully understand the potential of this combination therapy, but the initial findings are encouraging and offer a glimmer of hope in the fight against this challenging disease.

Date :
  1. Date Completed 2007-11-28
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

17145827

DOI: Digital Object Identifier

10.1158/1078-0432.CCR-06-1571

Related Literature

Article Analysis
・Side Effects of aldesleukin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.